Mirikizumab, a humanized IgG4-variant monoclonal antibody, has demonstrated encouraging outcomes in initiating and sustaining remission in individuals with moderate to highly active ulcerative colitis (UC), according to two phase 3 studies. Current UC medicines have drawbacks, including higher risks of infection or malignancy, nonresponse to initial therapy, and clinical benefit loss with time. The LUCENT-1 and LUCENT-2 studies were designed to evaluate the safety and effectiveness of mirikizumab in individuals with moderate to severe UC. During the 12-week induction phase, 1,162 patients received IV mirikizumab or placebo every four weeks. The maintenance study comprised 544 participants who were given subcutaneous mirikizumab or a placebo every four weeks for 40 weeks. The primary goal was to achieve clinical remission at weeks 12 and 40.

To know more: About the original article click here.